Re:NewCell Valuation
Is 0A5U undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0A5U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0A5U's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0A5U's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0A5U?
Other financial metrics that can be useful for relative valuation.
What is 0A5U's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | SEK 219.03m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6.1x |
Enterprise Value/EBITDA | -4.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0A5U's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.4x | ||
ITX Itaconix | 3.6x | 32.2% | UK£18.5m |
KRPZ Kropz | 0.5x | n/a | UK£12.0m |
BIOM Biome Technologies | 0.5x | 35.1% | UK£2.8m |
SGZ Scotgold Resources | 1x | n/a | UK£10.5m |
0A5U Re:NewCell | 1.1x | 83.0% | SEK 219.0m |
Price-To-Sales vs Peers: 0A5U is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (13.2x).
Price to Earnings Ratio vs Industry
How does 0A5U's PE Ratio compare vs other companies in the GB Chemicals Industry?
Price-To-Sales vs Industry: 0A5U is good value based on its Price-To-Sales Ratio (1.1x) compared to the UK Chemicals industry average (1.3x).
Price to Sales Ratio vs Fair Ratio
What is 0A5U's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.1x |
Fair PS Ratio | 0.9x |
Price-To-Sales vs Fair Ratio: 0A5U is expensive based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Oct ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Sep ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Aug ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Jul ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Jun ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
May ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Apr ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Mar ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Feb ’25 | SEK 9.58 | SEK 40.00 +317.5% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Jan ’25 | SEK 7.61 | SEK 40.00 +426.0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Dec ’24 | SEK 7.57 | SEK 40.00 +428.4% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Nov ’24 | SEK 12.09 | SEK 81.00 +570.0% | 81.5% | SEK 147.00 | SEK 15.00 | n/a | 2 |
Oct ’24 | SEK 67.90 | SEK 166.33 +145.0% | 14.4% | SEK 200.00 | SEK 147.00 | n/a | 3 |
Sep ’24 | SEK 88.00 | SEK 166.33 +89.0% | 14.4% | SEK 200.00 | SEK 147.00 | n/a | 3 |
Aug ’24 | SEK 79.65 | SEK 206.33 +159.1% | 24.8% | SEK 272.00 | SEK 147.00 | n/a | 3 |
Jul ’24 | SEK 80.20 | SEK 197.67 +146.5% | 31.2% | SEK 272.00 | SEK 121.00 | n/a | 3 |
Jun ’24 | SEK 75.75 | SEK 197.67 +160.9% | 31.2% | SEK 272.00 | SEK 121.00 | n/a | 3 |
May ’24 | SEK 80.15 | SEK 203.67 +154.1% | 34.7% | SEK 292.00 | SEK 119.00 | n/a | 3 |
Apr ’24 | SEK 81.77 | SEK 224.00 +173.9% | 30.6% | SEK 292.00 | SEK 130.00 | n/a | 3 |
Mar ’24 | SEK 92.02 | SEK 224.00 +143.4% | 30.6% | SEK 292.00 | SEK 130.00 | n/a | 3 |
Feb ’24 | SEK 95.35 | SEK 181.00 +89.8% | 38.1% | SEK 250.00 | SEK 112.00 | SEK 9.58 | 2 |
Jan ’24 | SEK 73.20 | SEK 181.00 +147.3% | 38.1% | SEK 250.00 | SEK 112.00 | SEK 7.61 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.